AU2021403827B2 - N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides - Google Patents
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides Download PDFInfo
- Publication number
- AU2021403827B2 AU2021403827B2 AU2021403827A AU2021403827A AU2021403827B2 AU 2021403827 B2 AU2021403827 B2 AU 2021403827B2 AU 2021403827 A AU2021403827 A AU 2021403827A AU 2021403827 A AU2021403827 A AU 2021403827A AU 2021403827 B2 AU2021403827 B2 AU 2021403827B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- oxoethyl
- cyanothiazolidin
- carboxamide
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024219819A AU2024219819B2 (en) | 2020-12-17 | 2024-09-18 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126593P | 2020-12-17 | 2020-12-17 | |
| US63/126,593 | 2020-12-17 | ||
| PCT/IB2021/061839 WO2022130270A1 (en) | 2020-12-17 | 2021-12-16 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024219819A Division AU2024219819B2 (en) | 2020-12-17 | 2024-09-18 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2021403827A1 AU2021403827A1 (en) | 2023-07-27 |
| AU2021403827B2 true AU2021403827B2 (en) | 2024-07-25 |
| AU2021403827A9 AU2021403827A9 (en) | 2024-10-17 |
Family
ID=79164845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021403827A Active AU2021403827B2 (en) | 2020-12-17 | 2021-12-16 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| AU2024219819A Active AU2024219819B2 (en) | 2020-12-17 | 2024-09-18 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024219819A Active AU2024219819B2 (en) | 2020-12-17 | 2024-09-18 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
| AU2023288645A1 (en) * | 2022-06-21 | 2025-02-13 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
| CN119562951A (zh) * | 2022-06-21 | 2025-03-04 | 阿斯利康(瑞典)有限公司 | N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 |
| WO2026119802A1 (en) | 2024-12-02 | 2026-06-11 | Astrazeneca Ab | Dosing regimen for the treatment of fap-mediated conditions |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| AU2001277754B2 (en) | 2000-08-10 | 2005-09-29 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
| JP2003026698A (ja) | 2000-09-27 | 2003-01-29 | Tokyo Inst Of Technol | 新規化合物、固定化物及び蛋白質のスクリーニング方法 |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| AU2004207731B2 (en) | 2003-01-31 | 2009-08-13 | Sanwa Kagaku Kenkyusho Co., Ltd. | Compound inhibiting dipeptidyl peptidase iv |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| TWI366438B (en) | 2004-08-12 | 2012-06-21 | Ishihara Sangyo Kaisha | Fungicidal composition containing acid amide derivative |
| WO2007017423A2 (en) | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| JP2010510246A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | アミド抗ウイルス化合物 |
| CN102884059B (zh) | 2010-03-11 | 2015-08-26 | 大日本住友制药株式会社 | N-酰基环胺衍生物或其可药用盐 |
| EP4706663A3 (en) | 2011-08-30 | 2026-05-20 | Trustees Of Tufts College | FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| EP2874632B1 (en) | 2012-07-23 | 2020-06-17 | Sphaera Pharma Pte. Ltd | Triazine compound having pi3k-alpha and mtor inhibiting activity |
| MX2016012573A (es) | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
| JP2017513954A (ja) | 2014-04-22 | 2017-06-01 | ニンバス アイリス, インコーポレイテッド | Irak阻害剤およびその使用 |
| AU2015315174B2 (en) | 2014-09-10 | 2019-12-12 | Epizyme, Inc. | Smyd inhibitors |
| WO2016061751A1 (en) * | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| CN108690043B (zh) | 2017-04-11 | 2019-10-18 | 东莞东阳光科研发有限公司 | 喹啉类衍生物及其制备方法和用途 |
| US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
| US11584744B2 (en) | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
| JP7365332B2 (ja) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Cdk8/19阻害薬としての新規ヘテロ環式化合物 |
| EP3700527A4 (en) | 2017-10-25 | 2021-03-10 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHOD OF USING THEM |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tlr7/8アンタゴニストおよびそれらの使用 |
| PH12020551205A1 (en) | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| SG11202100818RA (en) | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| US12662494B2 (en) | 2018-08-08 | 2026-06-23 | Sumitomo Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| TWI815954B (zh) | 2018-08-27 | 2023-09-21 | 日商住友製藥股份有限公司 | 光學活性氮雜雙環衍生物 |
| US10815241B2 (en) | 2018-08-27 | 2020-10-27 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active azabicyclo ring derivative |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
| US12559487B2 (en) | 2019-09-27 | 2026-02-24 | Sumitomo Pharma Co., Ltd. | Crosslinked optically active secondary amine derivative |
| BR112022008041A2 (pt) | 2019-11-06 | 2022-08-16 | Yuhan Corp | Compostos de pirrolidina e piperidina |
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
-
2021
- 2021-12-16 UY UY0001039569A patent/UY39569A/es unknown
- 2021-12-16 WO PCT/IB2021/061839 patent/WO2022130270A1/en not_active Ceased
- 2021-12-16 IL IL303655A patent/IL303655A/en unknown
- 2021-12-16 CR CR20230314A patent/CR20230314A/es unknown
- 2021-12-16 AU AU2021403827A patent/AU2021403827B2/en active Active
- 2021-12-16 US US18/257,123 patent/US20240101549A1/en active Pending
- 2021-12-16 PE PE2023001909A patent/PE20232046A1/es unknown
- 2021-12-16 JP JP2023536454A patent/JP7622229B2/ja active Active
- 2021-12-16 KR KR1020237023914A patent/KR20230122080A/ko active Pending
- 2021-12-16 CN CN202180084189.5A patent/CN116745291B/zh active Active
- 2021-12-16 CA CA3204318A patent/CA3204318A1/en active Pending
- 2021-12-16 AR ARP210103519A patent/AR124379A1/es unknown
- 2021-12-16 EP EP21834914.0A patent/EP4263535A1/en active Pending
- 2021-12-16 MX MX2023007287A patent/MX2023007287A/es unknown
- 2021-12-16 TW TW110147244A patent/TW202239407A/zh unknown
-
2023
- 2023-06-12 US US18/332,897 patent/US11858924B2/en active Active
- 2023-06-14 DO DO2023000124A patent/DOP2023000124A/es unknown
- 2023-06-15 CL CL2023001763A patent/CL2023001763A1/es unknown
- 2023-06-15 SA SA523441175A patent/SA523441175B1/ar unknown
- 2023-07-05 CO CONC2023/0008921A patent/CO2023008921A2/es unknown
- 2023-07-14 EC ECSENADI202353033A patent/ECSP23053033A/es unknown
-
2024
- 2024-09-18 AU AU2024219819A patent/AU2024219819B2/en active Active
-
2025
- 2025-01-15 JP JP2025005438A patent/JP7744538B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000124A (es) | 2023-07-09 |
| US20240101549A1 (en) | 2024-03-28 |
| MX2023007287A (es) | 2023-07-03 |
| WO2022130270A1 (en) | 2022-06-23 |
| EP4263535A1 (en) | 2023-10-25 |
| AU2021403827A1 (en) | 2023-07-27 |
| JP7744538B2 (ja) | 2025-09-25 |
| CO2023008921A2 (es) | 2023-07-21 |
| JP2025081297A (ja) | 2025-05-27 |
| ECSP23053033A (es) | 2023-08-31 |
| TW202239407A (zh) | 2022-10-16 |
| UY39569A (es) | 2022-07-29 |
| US11858924B2 (en) | 2024-01-02 |
| CL2023001763A1 (es) | 2023-11-17 |
| CN116745291B (zh) | 2026-06-30 |
| IL303655A (en) | 2023-08-01 |
| PE20232046A1 (es) | 2023-12-27 |
| CR20230314A (es) | 2023-08-18 |
| CA3204318A1 (en) | 2022-06-23 |
| US20230312550A1 (en) | 2023-10-05 |
| KR20230122080A (ko) | 2023-08-22 |
| AU2021403827A9 (en) | 2024-10-17 |
| SA523441175B1 (ar) | 2024-08-29 |
| JP7622229B2 (ja) | 2025-01-27 |
| AU2024219819B2 (en) | 2026-06-04 |
| JP2023554405A (ja) | 2023-12-27 |
| AU2024219819A1 (en) | 2024-10-10 |
| CN116745291A (zh) | 2023-09-12 |
| AR124379A1 (es) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7744538B2 (ja) | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド | |
| JP5116687B2 (ja) | がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤 | |
| TWI675833B (zh) | 布魯頓氏(bruton’s)酪胺酸激酶之聯芳基抑制劑 | |
| EP4549438A1 (en) | Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof | |
| CN112074520A (zh) | 四环杂芳基化合物 | |
| BRPI0714359A2 (pt) | inibidores de pirrolotriazina cinase | |
| EA020724B1 (ru) | Гетероциклическое соединение, лекарственное средство, включающее его, и способы его применения | |
| TW200831518A (en) | Imidazothiazole derivatives | |
| JP7266592B2 (ja) | ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用 | |
| EP2912037A1 (en) | 2-aminopyridine compounds | |
| CN110526929A (zh) | 芳杂环化合物、其药物组合物及其应用 | |
| WO2015125785A1 (ja) | 複数置換基を有するピラゾロン誘導体 | |
| US20230036854A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| US20240425523A1 (en) | Compounds for the Degradation of EGFR Kinase | |
| WO2020099882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| EA048482B1 (ru) | N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды | |
| WO2024259945A1 (zh) | 五元并六元含氮化合物、其制备方法和应用 | |
| EA051853B1 (ru) | N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды | |
| TW202500141A (zh) | 作為ripk1抑制劑的異㗁唑啶及其用途(二) | |
| HK40053673B (en) | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| FGA | Letters patent sealed or granted (standard patent) |